MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Search

Fortress Biotech Inc

Gesloten

2.9 -4.61

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

2.87

Max

3.04

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+375.41% upside

Dividenden

By Dow Jones

Volgende Winsten

12 nov 2025

Fortress Biotech Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

1 okt 2025, 15:07 UTC

Belangrijke Marktbewegers

Fortress Biotech Shares Drop After FDA Letter for CUTX-101 Manufacturing Facility

10 mrt 2025, 02:12 UTC

Acquisities, Fusies, Overnames

Checkpoint Controlling Shareholder Fortress Has Agreed to Vote in Favor of Transaction >524715.BY

10 mrt 2025, 02:12 UTC

Acquisities, Fusies, Overnames

Sun Pharma, Checkpoint Transaction Expected to Complete in 2Q 2025 >524715.BY

10 mrt 2025, 02:11 UTC

Acquisities, Fusies, Overnames

Sun Pharma, Checkpoint, Fortress Biotech Enter Into Royalty Agreement >524715.BY

10 mrt 2025, 02:11 UTC

Acquisities, Fusies, Overnames

Checkpoint Shareholders Entitled to Receive Up to Additional $0.70 if Cosibelimab if Approved in EU Prior to Certain Deadlines >524715.BY

10 mrt 2025, 02:10 UTC

Acquisities, Fusies, Overnames

Checkpoint Shareholders to Receive Upfront Cash Payment of $4.10/Share, Contingent Value Right >524715.BY

10 mrt 2025, 02:10 UTC

Acquisities, Fusies, Overnames

Sun Pharma to Acquire Checkpoint Therapeutics >524715.BY CKPT

10 mrt 2025, 02:06 UTC

Acquisities, Fusies, Overnames

Sun Pharma To Acquire Checkpoint Therapeutics >524715.BY CKPT

Peer Vergelijking

Prijswijziging

Fortress Biotech Inc Prognose

Koersdoel

By TipRanks

375.41% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 14.5Ā USDĀ  375.41%

Hoogste 17Ā USD

Laagste 12Ā USD

Gebaseerd op 2 Wall Street-analisten die 12-maands prijsdoelen bieden voor Fortress Biotech Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

2 ratings

2

Buy

0

Hold

0

Sell

Financieel

$

help-icon Live chat